NCT06285019 2024-02-29
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Unknown
Clinical Trials
21 trialsNCT05250843 2023-10-13
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2/3 Unknown
NCT05010434 2023-09-21
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT06029829 2023-09-08
The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.
China Three Gorges University, Yichang, China
Phase 2 Unknown
NCT05971199 2023-08-02
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05616390 2023-03-21
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05029973 2023-02-08
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05225116 2023-02-08
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown
NCT05617430 2022-11-15
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04718909 2022-11-10
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT04174781 2022-06-09
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
Zhejiang University
Phase 2 Unknown
NCT05363722 2022-05-06
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05166772 2021-12-22
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04796025 2021-09-28
T-Double
Sun Yat-sen University
Phase 2 Unknown
NCT04843943 2021-04-14
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
Fudan University
Phase 1/2 Unknown
NCT04167293 2021-03-23
ISBRT01
Sun Yat-sen University
Phase 2/3 Unknown
NCT04042805 2021-03-02
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03794440 2021-01-22
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2/3 Unknown
NCT04104074 2020-07-07
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown